Loading
A phase 2 trial of Aglatimagene besadenovec in prostate cancer, run by Candel Therapeutics, Inc., active and no longer recruiting.
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) is a phase 2 interventional study registered as NCT02768363 by Candel Therapeutics, Inc., with 187 participants enrolled, started 2016-05 and due to reach its primary completion in 2024-11. Interventions recorded: aglatimagene besadenovec, placebo, valacyclovir. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Aglatimagene besadenovec, Candel Therapeutics, Prostate cancer.
Shares Aglatimagene besadenovec, Candel Therapeutics, Prostate cancer.
Shares Localised prostate cancer, very low and low risk, Prostate cancer.
Shares Localised prostate cancer, very low and low risk, Prostate cancer.
Shares Localised prostate cancer, very low and low risk, Prostate cancer.
Shares Localised prostate cancer, very low and low risk, Prostate cancer.